Immucell Stock Buy Hold or Sell Recommendation
| ICCC Stock | USD 5.04 0.01 0.20% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding ImmuCell is 'Strong Sell'. Macroaxis provides ImmuCell buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ImmuCell positions. The advice algorithm takes into account all of ImmuCell's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting ImmuCell's buy or sell advice are summarized below:
Real Value 7.1 | Target Price 14 | Hype Value 5.06 | Market Value 5.04 | Naive Value 4.92 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell ImmuCell given historical horizon and risk tolerance towards ImmuCell. When Macroaxis issues a 'buy' or 'sell' recommendation for ImmuCell, the advice is generated through an automated system that utilizes algorithms and statistical models.
ImmuCell |
Execute ImmuCell Buy or Sell Advice
The ImmuCell recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on ImmuCell. Macroaxis does not own or have any residual interests in ImmuCell or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute ImmuCell's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
ImmuCell Trading Alerts and Improvement Suggestions
| ImmuCell generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 17.47 M. Net Loss for the year was (6.3 M) with profit before overhead, payroll, taxes, and interest of 7.65 B. | |
| About 28.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by David Tomsche of 485 shares of ImmuCell at 7.77 subject to Rule 16b-3 |
ImmuCell Returns Distribution Density
The distribution of ImmuCell's historical returns is an attempt to chart the uncertainty of ImmuCell's future price movements. The chart of the probability distribution of ImmuCell daily returns describes the distribution of returns around its average expected value. We use ImmuCell price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of ImmuCell returns is essential to provide solid investment advice for ImmuCell.
| Mean Return | -0.08 | Value At Risk | -2.93 | Potential Upside | 2.90 | Standard Deviation | 1.89 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of ImmuCell historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
ImmuCell Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ImmuCell is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ImmuCell backward and forwards among themselves. ImmuCell's institutional investor refers to the entity that pools money to purchase ImmuCell's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Strategic Investment Advisors Inc | 2023-12-31 | 31 K | Hightower Advisors, Llc | 2023-12-31 | 21.4 K | Prosperity Planning, Inc. | 2024-03-31 | 16 K | Blackrock Inc | 2023-12-31 | 15.5 K | Wealth Effects Llc | 2023-12-31 | 15.4 K | Citadel Advisors Llc | 2023-09-30 | 15 K | Mesirow Fin Investmt Mgmt Intl Equity | 2023-12-31 | 12.2 K | Essex Financial Services, Inc. | 2023-12-31 | 11 K | Mission Wealth Management, Llc | 2023-12-31 | 10 K | Vanguard Group Inc | 2023-12-31 | 206.6 K | Renaissance Technologies Corp | 2023-12-31 | 126.2 K |
ImmuCell Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (186.6K) | 425.7K | (997.5K) | (2.9M) | (2.1M) | (2.0M) | |
| Free Cash Flow | (1.2M) | (2.8M) | (1.7M) | (5.5M) | 2.7M | 2.8M | |
| Depreciation | 2.3M | 2.3M | 2.5M | 2.5M | 2.7M | 2.8M | |
| Other Non Cash Items | 19.4K | (780.4K) | 18.6K | 28.8K | (2.7M) | (2.6M) | |
| Capital Expenditures | 1.4M | 4.1M | 2.6M | 4.0M | 3.3M | 3.5M | |
| Net Income | (1.3M) | (1.0M) | (78.3K) | (2.5M) | (6.3M) | (6.0M) | |
| End Period Cash Flow | 6.3M | 6.9M | 10.2M | 5.8M | 6.7M | 7.0M | |
| Change In Cash | 3.8M | 656.6K | 3.2M | (4.4M) | (6.8M) | (6.5M) | |
| Investments | (2.0M) | (2.6M) | (1.6M) | (4.0M) | (3.4M) | (3.2M) | |
| Change Receivables | (306.3K) | 411.7K | (732.6K) | (132.4K) | (119.1K) | (125.1K) | |
| Net Borrowings | (1.4M) | 2.0M | (368.3K) | 1.1B | 1.3B | 1.3B | |
| Change To Netincome | 357.3K | (644.6K) | 186.0K | 287.4M | 330.5M | 347.0M |
ImmuCell Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to ImmuCell or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that ImmuCell's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a ImmuCell stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.07 | |
β | Beta against NYSE Composite | -0.19 | |
σ | Overall volatility | 1.70 | |
Ir | Information ratio | -0.09 |
ImmuCell Volatility Alert
ImmuCell exhibits very low volatility with skewness of -0.11 and kurtosis of 0.41. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure ImmuCell's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact ImmuCell's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.ImmuCell Fundamentals Vs Peers
Comparing ImmuCell's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze ImmuCell's direct or indirect competition across all of the common fundamentals between ImmuCell and the related equities. This way, we can detect undervalued stocks with similar characteristics as ImmuCell or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of ImmuCell's fundamental indicators could also be used in its relative valuation, which is a method of valuing ImmuCell by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare ImmuCell to competition |
| Fundamentals | ImmuCell | Peer Average |
| Return On Equity | -0.21 | -0.31 |
| Return On Asset | -0.0736 | -0.14 |
| Profit Margin | (0.33) % | (1.27) % |
| Operating Margin | (0.09) % | (5.51) % |
| Current Valuation | 54.7 M | 16.62 B |
| Shares Outstanding | 7.75 M | 571.82 M |
| Shares Owned By Insiders | 28.04 % | 10.09 % |
| Shares Owned By Institutions | 13.48 % | 39.21 % |
| Number Of Shares Shorted | 6.12 K | 4.71 M |
| Price To Earning | 195.00 X | 28.72 X |
| Price To Book | 1.56 X | 9.51 X |
| Price To Sales | 2.23 X | 11.42 X |
| Revenue | 17.47 M | 9.43 B |
| Gross Profit | 7.65 B | 27.38 B |
| EBITDA | (3.01 M) | 3.9 B |
| Net Income | (6.3 M) | 570.98 M |
| Cash And Equivalents | 11.04 M | 2.7 B |
| Cash Per Share | 1.43 X | 5.01 X |
| Total Debt | 12.48 M | 5.32 B |
| Debt To Equity | 0.36 % | 48.70 % |
| Current Ratio | 6.91 X | 2.16 X |
| Book Value Per Share | 3.23 X | 1.93 K |
| Cash Flow From Operations | 2.7 M | 971.22 M |
| Short Ratio | 0.94 X | 4.00 X |
| Earnings Per Share | (0.75) X | 3.12 X |
| Target Price | 14.0 | |
| Number Of Employees | 74 | 18.84 K |
| Beta | 0.6 | -0.15 |
| Market Capitalization | 38.99 M | 19.03 B |
| Total Asset | 44.86 M | 29.47 B |
| Retained Earnings | (6.23 M) | 9.33 B |
| Working Capital | 10.92 M | 1.48 B |
| Current Asset | 4.49 M | 9.34 B |
Note: Acquisition by David Tomsche of 485 shares of ImmuCell at 7.77 subject to Rule 16b-3 [view details]
ImmuCell Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as ImmuCell . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | 9.2 T | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 5.04 | |||
| Day Typical Price | 5.04 | |||
| Price Action Indicator | 0.005 | |||
| Period Momentum Indicator | 0.01 | |||
| Relative Strength Index | 66.01 |
About ImmuCell Buy or Sell Advice
When is the right time to buy or sell ImmuCell? Buying financial instruments such as ImmuCell Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 10.3M | 12.5M | 14.4M | 15.1M | Total Assets | 44.5M | 44.9M | 51.6M | 54.2M |
Use Investing Ideas to Build Portfolios
In addition to having ImmuCell in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Shipbuilding Railroad Equipment Thematic Idea Now
Shipbuilding Railroad Equipment
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Shipbuilding Railroad Equipment theme has 16 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Shipbuilding Railroad Equipment Theme or any other thematic opportunities.
| View All Next | Launch |
Check out ImmuCell Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.Note that the ImmuCell information on this page should be used as a complementary analysis to other ImmuCell's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Complementary Tools for ImmuCell Stock analysis
When running ImmuCell's price analysis, check to measure ImmuCell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmuCell is operating at the current time. Most of ImmuCell's value examination focuses on studying past and present price action to predict the probability of ImmuCell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmuCell's price. Additionally, you may evaluate how the addition of ImmuCell to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is ImmuCell's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmuCell. If investors know ImmuCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmuCell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.63) | Earnings Share (0.75) | Revenue Per Share 2.255 | Quarterly Revenue Growth 0.303 | Return On Assets (0.07) |
The market value of ImmuCell is measured differently than its book value, which is the value of ImmuCell that is recorded on the company's balance sheet. Investors also form their own opinion of ImmuCell's value that differs from its market value or its book value, called intrinsic value, which is ImmuCell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmuCell's market value can be influenced by many factors that don't directly affect ImmuCell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmuCell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.